Holen Sie sich die Stockscreener-App
0.3544
13.73%
-0.0564
Schlusskurs vom Vortag:
$0.4108
Offen:
$0.448
24-Stunden-Volumen:
474.36K
Relative Volume:
2.36
Marktkapitalisierung:
$6.39M
Einnahmen:
$9.37M
Nettoeinkommen (Verlust:
$-8.45M
KGV:
-0.4375
EPS:
-0.81
Netto-Cashflow:
$-7.27M
1W Leistung:
-6.74%
1M Leistung:
-55.70%
6M Leistung:
-79.63%
1J Leistung:
-81.49%
1-Tages-Spanne:
$0.3011
$0.448
1-Wochen-Bereich:
$0.3011
$0.448
52-Wochen-Spanne:
$0.3011
$3.1626
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
Firmenname
Bioaffinity Technologies Inc
Sektor
Branche
Telefon
210-698-5334
Adresse
22211 WEST INTERSTATE-10, SAN ANTONIO
Vergleichen Sie BIAF mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIAF
Bioaffinity Technologies Inc
|
0.3544 | 6.39M | 9.37M | -8.45M | -7.27M | -0.81 |
|
TMO
Thermo Fisher Scientific Inc
|
508.90 | 191.99B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
204.09 | 145.87B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
117.33 | 33.47B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IDXX
Idexx Laboratories Inc
|
406.29 | 33.04B | 3.90B | 887.87M | 798.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
181.43 | 31.99B | 15.41B | 1.37B | 2.11B | 7.50 |
Bioaffinity Technologies Inc Aktie (BIAF) Neueste Nachrichten
Physicians’ Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer - Joplin Globe
Revolutionary Lung Cancer Test Saves $895M: Doctor's Case Study Reveals Game-Changing Results - StockTitan
SA biotech plans big cuts to grow core company - The Business Journals
bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth - 01Net
bioAffinity announces cost cuts to boost CyPath Lung sales By Investing.com - Investing.com South Africa
BioAffinity accelerates CyPath Lung amid $4M in annual cost savings at PPLS - TipRanks
bioAffinity announces cost cuts to boost CyPath Lung sales - Investing.com
Can bioAffinity's $4M Cost-Cutting Plan Transform Its Cancer Detection Business? - StockTitan
bioAffinity Technologies, Inc. (NASDAQ:BIAF) Sees Large Drop in Short Interest - Defense World
bioAffinity stock hits 52-week low at $0.55 amid market challenges - Investing.com Canada
bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million - 01Net
BioAffinity Technologies Raises $1.4 Million After Warrant Exercise -February 26, 2025 at 12:59 pm EST - Marketscreener.com
How Will bioAffinity's $1.4M Capital Raise Impact Existing Shareholders? - StockTitan
bioAffinity's $1.4M Cash Injection Comes With 61% Warrant DiscountWhat's the Real Cost? - StockTitan
WallachBeth Capital Announces bioAffinity Technologies Warrant I - GuruFocus.com
How bioAffinity's $1.4M Warrant Deal Affects Shareholder Value: Dilution vs. Cash Injection - StockTitan
bioAffinity's $1.4M Cash Infusion Comes at a Cost: Warrant Price Slashed by 61% - StockTitan
WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million - Nasdaq
Early lung cancer diagnosis saves 52-year-old Indian man’s life - Mugglehead
Zacks Initiates Coverage of bioAffinity With Neutral Recommendation - MSN
bioAffinity Technologies faces Nasdaq delisting over price - MSN
bioAffinity Technologies faces Nasdaq delisting over price By Investing.com - Investing.com Nigeria
British scientists develop lung cancer blood test that gives results in 40 minutes - Mugglehead
The Zacks Analyst Blog Highlights Amazon, Bank of America, Caterpillar, NVE and bioAffinity - Nasdaq
Top Research Reports for Amazon.com, Bank of America & Caterpillar - Nasdaq
bioAffinity Technologies (NASDAQ:BIAFW) Trading Down 16.7% – Here’s Why - Defense World
Global Drug Screening Market Is Forecasted to Reach $19.5 Billion By 2029 - GlobeNewswire
Press Telegram - Financial Content
Biotricity and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
bioAffinity Technologies (BIAF) Stock Price, News & Analysis - MarketBeat
BIOAFFINITY TECHNOLOGIES, INC. : Other Events, Financial Statements and Exhibits (form 8-K) - Marketscreener.com
bioAffinity Technologies secures Australian patent for ‘CyPath Lung’ spit test - Mugglehead
bioAffinity secures Australian patent for lung cancer test - MSN
bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic - BioSpace
bioAffinity Technologies stock hits 52-week low at $0.65 - MSN
Biotech company CEO receives pay bump - San Antonio Business Journal
bioAffinity Technologies Increases CEO Maria Zannes’ Annual Base Salary to $300,000 - Defense World
bioAffinity Technologies Adjusts CEO Compensation Package - TipRanks
bioAffinity Technologies CEO receives salary increase - Investing.com
bioAffinity Technologies (NASDAQ:BIAFW) Trading Up 4.7% – Time to Buy? - Defense World
bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung - BioSpace
bioAffinity's Breakthrough Lung Cancer Test Shows 92% Accuracy, Could Save Medicare $379M - StockTitan
Enlivex CEO to Showcase Breakthrough Allocetra Cell Therapy on Bloomberg TV Special Feature - StockTitan
**bioAffinity Technologies Reports Results of 2024 Special Meeting** - Defense World
bioAffinity Technologies (NASDAQ:BIAF) Shares Down 2% – Here’s Why - Defense World
bioAffinity Technologies Boosts Sales with CyPath Lung - Yahoo Finance
bioAffinity Technologies (NASDAQ:BIAFW) Trading Down 25.7% – Time to Sell? - Defense World
San Antonio biotech company looks to expand in 2025 - The Business Journals
Finanzdaten der Bioaffinity Technologies Inc-Aktie (BIAF)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):